Abstract
The in vivo biodistribution and pharmacokinetics of 1329, a novel spectinamide antibiotic with anti-tubercular activity, were studied during intravenous administration of an tritium-labeled compound for nine consecutive, 12-hourly doses to rats. Serial blood samples were collected after the first and the eighth dose, and major organs and tissues were collected 1 h after the ninth dose. Urinary and fecal excretion was monitored throughout the dosing period. Radioactivity in the collected samples was assessed by scintillation counting. During the course of treatment, 86.6% of the administered radioactivity was recovered in urine, feces, organs, and muscle tissue. Urinary excretion was the major route of elimination, with 70% of radioactivity recovered from urine and 12.6% from feces. The time profiles of radioactivity in serum after the first and the eighth dose were identical for the first 2 h post-dose, with similar Cmax (3.39 vs. 3.55 mCi/L) and AUC0−τ (5.08 vs. 5.17 mCi • h/L), indicating no substantial accumulation of 1329 during multiple dosing. Radioactivity in major target organs for pulmonary tuberculosis infection, the lungs and spleen, was 2.79- and 3.06-fold higher than in the blood. Similarly, the intracellular uptake of 1329 into macrophages was sixfold higher than for streptomycin. Overall, these observations suggest biodistribution properties favorable for targeting pulmonary tuberculosis infections.
References
Lee RE, Hurdle JG, Liu J, Bruhn DF, Matt T, Scherman M, et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med. 2014;20(2):152–8. doi:10.1038/nm.3458.
Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci. 2002;91(1):18–31.
Mdluli K, Kaneko T, Upton A. The tuberculosis drug discovery and development pipeline and emerging drug targets. Cold Spring Harb Perspect Med. 2015;5(6). doi: 10.1101/cshperspect.a021154.
Usynin IF, Khar’kovsky AV, Balitskaya NI, Panin LE. Gadolinium chloride-induced Kupffer cell blockade increases uptake of oxidized low-density lipoproteins by rat heart and aorta. Biochemistry (Mosc). 1999;64(6):620–4.
Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe. 2008;3(6):399–407. doi:10.1016/j.chom.2008.05.006.
Muir KT, Gomeni RO. Non-compartmental analysis. In: Bonate PL, Howard DR, editors. Pharmacokinetics in drug development: clinical study design and analysis, vol. 1. Arlington: AAPS Press; 2004. p. 235–58.
Shaffer CL, Gunduz M, Thornburgh BA, Fate GD. Using a tritiated compound to elucidate its preclinical metabolic and excretory pathways in vivo: exploring tritium exchange risk. Drug Metab Dispos: Biol Fate Chem. 2006;34(9):1615–23. doi:10.1124/dmd.106.010934.
Yang S, Zhang Q, Chen J, Han D, Zhao D, Chen X. Pharmacokinetics and disposition study of calf thymus DNA in rats by applying 3H-labeling method. J Pharm Biomed Anal. 2012;64-65:35–9. doi:10.1016/j.jpba.2012.02.012.
Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17–43. doi:10.1080/03602530600952172.
Madhura DB, Trivedi A, Rathi C, Liu J, Lee RE, Meibohm B. Pharmacokinetic evaluation of novel spectinamides. AAPS J. 2012;14(S2):W5350.
Wagner JG. Drug accumulation. J Clin Pharmacol. 1967;7(2):84–8.
Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35(8):763–6.
Knechel NA. Tuberculosis: pathophysiology, clinical features, and diagnosis. Crit Care Nurse. 2009;29(2):34–43. doi:10.4037/ccn2009968.
Acknowledgments
This research was supported by grant R01AI090810 by the National Institute of Allergy and Infectious Diseases and grant S10OD016226, Office of the Director, National Institutes of Health and the American Lebanese Syrian Associated Charities (ALSAC). We thank Tom Mohaupt, Jennings Payne, Kellen Thuo, and Warner Turner (Radiation Safety Division, St. Jude Children’s Research Hospital, Memphis, TN) for their help in determining the total and specific activity of the radiolabeled compound. We thank Dr. Feng Yin and Dr. James T. Dalton (GTx Inc., Memphis, TN) for the opportunity to use their sample oxidation equipment.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All animal experiments were conducted in accordance with the Animal Welfare Act and the Public Health Service Policy on Humane Care and Use of Laboratory Animals. The study protocol was approved by the Institutional Animal Care and Use Committee and the Radiation Safety Committee of the University of Tennessee Health Science Center.
Conflict of Interest
J.L., R.E.L., and B.M. disclose intellectual property rights ownership associated with the spectinamide series.
ELECTRONIC SUPPLEMENTARY MATERIAL
Below is the link to the electronic supplementary material.
MOESM 1
(PDF 459 kb)
Rights and permissions
About this article
Cite this article
Madhura, D.B., Trivedi, A., Liu, J. et al. Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis. AAPS J 18, 788–791 (2016). https://doi.org/10.1208/s12248-016-9900-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-016-9900-7